Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)
Data Compares Briakinumab (ABT-874) to Etanercept, Methotrexate and Placebo in Psoriasis
13-Oct-2010 -
In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with ...
Abbott
acute myocardial infarction
biologics
+13